Tracers / [64Cu]Cu-sartate

[64Cu]Cu-sartate

Also written as Cu-64 SARTATE; SARTATE
Radionuclide
Cu-64 t½ 762 min
Modality
PET
Production route
Stage
first-in-human
Syntheses indexed
4

What it is

Compound class
Sarcophagine-conjugated somatostatin analog peptide (SarTATE, MeCOSar-Tyr3-octreotate)
Target / mechanism
Somatostatin receptor (SSTR) binding via octreotate peptide PMID 30442752
Clinical application
PET/CT imaging of somatostatin receptor-positive neuroendocrine tumors, with potential for prospective dosimetry for PRRT PMID 30442752
Theranostic pair
<a href="/tracers/cu67-sartate/">cu67-sartate</a>

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
30442752
2019 J Nucl Med
Manual synthesisSarTATE42201774
2026 Inorg Chem
Copper-64 (46.25 MBq, 1.25 mCi) in 0.1 M HCl was neutralized with PBS and NaOH and combined with SarTATE
Kit-based preparation41754861
2026 Pharmaceuticals (Basel)
[64Cu]Cu-SAR-TATE
30442752
2019 J Nucl Med

Need this precursor?We can point you to suppliers for [64Cu]Cu-sartate, or handle the enquiry for you.

Get in touch

Quality control Derived from the published synthesis

Ph. Eur. monograph
USP monograph
AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impurities
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [64Cu]Cu-sartate.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with Cu-64. Also seen with Cu-67[1] (too few articles for own row). Stage set/updated at stage 23 from PMID 30442752: 'we have performed a first-time-in-humans trial of 64Cu-MeCOSar-Tyr3-octreotate (64Cu-SARTATE) to assess its safety and ability to localize disease at early and late imaging time-points'.